USE OF SEROTONIN RECEPTOR AGONISTS FOR TREATMENT OF MOVEMENT DISORDERS
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to the combined use of compounds which are activators of the KCNQ family potassium ion channels and compounds which are serotonin 5-HT1 receptor agonists. The combined use of KCNQ channel activators and 5-HT1 receptor agonists is useful in the treatment of for example movement disorders. The present invention further relates to pharmaceutical compositions, methods of treatments and kits of parts.
-
Citations
66 Claims
-
1-46. -46. (canceled)
-
47. A method for treatment, prevention or alleviation of movement disorders comprising:
-
one or more steps of administration of an effective amount of a pharmaceutical composition comprising a KCNQ channel activator, or a pharmaceutically acceptable derivative thereof, and one or more steps of administration of an effective amount of a pharmaceutical composition comprising a serotonin 5-HT1 receptor agonist, or a pharmaceutical acceptable derivative thereof, to an individual in need thereof. - View Dependent Claims (48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)
-
- 62. A pharmaceutical composition or kit of parts comprising a KCNQ channel activator and a serotonin 5-HT1A receptor agonist, or pharmaceutically acceptable derivatives thereof.
Specification